Zacks Investment Research upgraded shares of CONCEPTUS INC (CPTS) from NEUTRAL to OUTPERFORM on July 05, 2012, with a target price of $21.70.
Conceptus, Inc. designs and develops minimally invasive devices for reproductive medical applications. Conceptus' focus is to develop its STOP non-surgical permanent contraception device for women. STOP is designed to be a less-invasive, safer, and less costly alternative to surgical sterilization, more commonly known as tubal ligation. The STOP device is designed to achieve contraception by elliciting a tissue response which occludes the fallopian tubes.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CONCEPTUS INC (CPTS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment